Monoclonal antibodies have an important and wide-ranging role in many areas of biomedical research and this volume is among the first to combine technical and clinical aspects of the subject. Monoclonal antibodies provide highly specific reagents with which to identify, analyse, quantitate and manipulate molecules, both in solution and in solid phase, such as at a cell surface. The aim of this book is to provide a unique combination of information concerning the production (by both cellular and molecular biology techniques), and structural and functional characteristics of monoclonal antibodies, together with detailed discussions of the various analytic, diagnostic and therapeutic applications of these antibodies in many areas of clinical medicine, including histopathology, oncology, transplantation, infectious diseases, rheumatology, haematology and dermatology.
Monoclonal antibodies
POSTGRADUATE MEDICAL SCIENCE

This important new series is based on the successful and internationally well-regarded specialist training programme at the Royal Postgraduate Medical School in London. Each volume provides an integrated and self-contained account of a key area of medical science, developed in conjunction with the course organisers and including contributions from specially invited authorities.

The aim of the series is to provide biomedical and clinical scientists with a reliable introduction to the theory and to the technical and clinical applications of each topic.

The volumes will be a valuable resource and guide for trainees in the medical and biomedical sciences and for laboratory-based scientists.

In the series:

* Radiation protection of patients by R. Wootton

* Image analysis in histology: conventional and confocal microscopy by D. Springall, R. Wootton and J. Polak
POSTGRADUATE MEDICAL SCIENCE

Monoclonal antibodies

Production, engineering and clinical application

EDITED BY

MARY A. RITTER and
HEATHER M. LADYMAN

Department of Immunology
Royal Postgraduate Medical School

Published in association with the Royal Postgraduate Medical School
University of London by

CAMBRIDGE UNIVERSITY PRESS
Contents

1 Introduction
   M. A. Ritter
   1
   1.1 Introduction
   1
   1.2 Generation of an immune response
   1
   1.3 Antibody structure
   2
   1.4 Generation of the B cell repertoire
   4
   1.5 What is a monoclonal antibody?
   6
   1.6 The aim of this book
   8
   1.7 References
   8

2 Production of monoclonal antibodies
   H. M. Ladyman and M. A. Ritter
   9
   2.1 Introduction
   9
   2.2 Antigens and immunization
   9
   2.3 Cell fusion
   15
   2.4 Growth and selection of hybrids
   18
   2.5 Cloning techniques
   22
   2.6 Cell maintenance and bulk production of antibody
   24
   2.7 Characterization and purification of antibody
   26
   2.8 Storage
   30
   2.9 Analysis of the structure of the antigen to which your
       monoclonal antibody binds
   31
   2.10 Summary
   32
   2.11 References
   32

3 Antigen–antibody interactions: how affinity and kinetics affect assay
   design and selection procedures
   R. J. Morris
   34
   3.1 Introduction
   34
   3.2 What is affinity?
   34
   3.3 Kinetics of association and dissociation
   37
   3.4 Sensitivity, and its relationship to affinity
   41
   3.5 Other parameters affecting affinity
   44
   3.6 The nature of a protein epitope and its influence on antibody
       binding
   50
Contents

3.7 So what is antibody specificity? 53
3.8 Summary 56
3.9 References 57

4 Production and characterization of synthetic peptide-derived antibodies 60
K. M. Price
4.1 Introduction 60
4.2 Prediction and selection of antigenic determinants 61
4.3 Conjugation 63
4.4 Immunization 66
4.5 Screening 66
4.6 Epitope detection and analysis 69
4.7 Appendix 78
4.8 References 82

5 Human monoclonal antibodies: production, use, problems 85
A. Sa’adu and A. Zumla
5.1 Production of human monoclonal antibodies 85
5.2 Use of human monoclonal antibodies 90
5.3 Problems with human monoclonal antibody production 97
5.4 Conclusion 106
5.5 References 106

6 Bispecific monoclonal antibodies 121
S. Songsivilai and P. J. Lachmann
6.1 Introduction 121
6.2 Production of bispecific monoclonal antibodies 123
6.3 Applications of bispecific antibodies: current status and future development 132
6.4 References 136

7 Production of antibodies using phage display libraries 142
A. J. T. George
7.1 Introduction 142
7.2 Filamentous phage 143
7.3 Filamentous phage as expression vectors 144
7.4 Antibody selection on phage 146
7.5 Recombinant antibody fragments 154
7.6 Conclusions 159
7.7 References 160

8 Genetic manipulation of monoclonal antibodies 166
N. S. Courtenay-Luck
8.1 Introduction 166
8.2 Humanization 166
8.3 Recombinant antibody fragments 170
8.4 Discussion 175
8.5 References 177
Contents

9  Monoclonal antibodies in diagnostic immunoassays  180
    D. B. Cook and C. H. Self
    9.1  Introduction  180
    9.2  Advantages and pitfalls of using monoclonal antibodies  183
    9.3  Specificity  185
    9.4  Small molecular weight analytes  188
    9.5  Endogenous interference in immunoassays  190
    9.6  High-dose hook phenomenon  193
    9.7  Use of established labelling technology  194
    9.8  Sensitivity  194
    9.9  Speed  195
    9.10  Convenience  196
    9.11  Methods of detection  197
    9.12  Fibre optic sensors  201
    9.13  Future of monoclonal antibodies in diagnostics  201
    9.14  References  203

10A  Monoclonal antibodies in oncology: diagnostic pathology  209
     A. Colfor and P. A. Hall
     10A.1  Introduction  209
     10A.2  Genotype and phenotype  209
     10A.3  Use of immunohistochemistry in diagnostic pathology  210
     10A.4  Use of immunohistochemistry in diagnosis  210
     10A.5  Immunohistochemistry as an educational aid  214
     10A.6  Use in prognosis  214
     10A.7  Histogenesis versus differentiation  216
     10A.8  Future prospects  218
     10A.9  Conclusion  219
     10A.10  References  219

10B  Monoclonal antibodies in oncology: in-vivo targeting for immunoscintigraphy and therapy of human malignancies  222
     A. Bamias and A. A. Epenotos
     10B.1  Introduction  222
     10B.2  Immunoscintigraphy  223
     10B.3  Immunotherapy  229
     10B.4  Conclusion  238
     10B.5  References  238

11A  Monoclonal antibodies in infectious disease: diagnosis  247
     T. G. Wreghitt and J. J. Gray
     11A.1  Introduction  247
     11A.2  Respiratory infections  247
     11A.3  Gastroenteritis  248
     11A.4  Hepatitis  249
     11A.5  Neurological/congenital infections  250
     11A.6  Meningitis  250
     11A.7  Encephalitis  251
     11A.8  Sexually transmitted disease  252
<table>
<thead>
<tr>
<th></th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>11A.9</td>
<td>Infection in the immunocompromised host</td>
</tr>
<tr>
<td>11A.10</td>
<td>References</td>
</tr>
</tbody>
</table>

**11B** Monoclonal antibodies in infectious disease: prophylaxis and therapy  
*J. Cohen*

<table>
<thead>
<tr>
<th></th>
<th>contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>11B.1</td>
<td>Introduction</td>
</tr>
<tr>
<td>11B.2</td>
<td>Bacterial infections</td>
</tr>
<tr>
<td>11B.3</td>
<td>Viral and chlamydial infections</td>
</tr>
<tr>
<td>11B.4</td>
<td>Additional applications of monoclonal antibodies</td>
</tr>
<tr>
<td>11B.5</td>
<td>Conclusions</td>
</tr>
<tr>
<td>11B.6</td>
<td>References</td>
</tr>
</tbody>
</table>

**12A** Monoclonal antibodies in transplantation: immunohistology  
*M. L. Rose*

<table>
<thead>
<tr>
<th></th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>12A.1</td>
<td>Introduction</td>
</tr>
<tr>
<td>12A.2</td>
<td>Nature of the infiltrate</td>
</tr>
<tr>
<td>12A.3</td>
<td>Major histocompatibility complex antigens</td>
</tr>
<tr>
<td>12A.4</td>
<td>Adhesion molecules</td>
</tr>
<tr>
<td>12A.5</td>
<td>Cytokines</td>
</tr>
<tr>
<td>12A.6</td>
<td>References</td>
</tr>
</tbody>
</table>

**12B** Experimental studies on *in-vivo* immunosuppression  
*N. M. Parish and A. Cooke*

<table>
<thead>
<tr>
<th></th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>12B.1</td>
<td>Introduction</td>
</tr>
<tr>
<td>12B.2</td>
<td>Monoclonal antibody treatments directed towards T cell surface markers</td>
</tr>
<tr>
<td>12B.3</td>
<td>Monoclonal antibody therapies targeted at antigen-presenting cells</td>
</tr>
<tr>
<td>12B.4</td>
<td>Monoclonal antibody therapies targeting cytokines</td>
</tr>
<tr>
<td>12B.5</td>
<td>Monoclonal antibody therapies targeting adhesion molecules</td>
</tr>
<tr>
<td>12B.6</td>
<td>Monoclonal antibodies directed towards miscellaneous cell markers</td>
</tr>
<tr>
<td>12B.7</td>
<td>References</td>
</tr>
</tbody>
</table>

**12C** Monoclonal antibodies in transplantation: prophylaxis and treatment of graft-versus-host disease after bone marrow transplantation  
*L. Boström and O. Ringden*

<table>
<thead>
<tr>
<th></th>
<th>Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>12C.1</td>
<td>Introduction</td>
</tr>
<tr>
<td>12C.2</td>
<td>Prevention of GVHD with <em>in-vitro</em> use of monoclonal antibodies</td>
</tr>
<tr>
<td>12C.3</td>
<td>Randomized clinical studies comparing pharmacological GVHD prophylaxis with T cell depletion</td>
</tr>
<tr>
<td>12C.4</td>
<td>Monoclonal antibodies <em>in vivo</em> for prevention of GVHD</td>
</tr>
<tr>
<td>12C.5</td>
<td>Treatment of GVHD with monoclonal antibodies</td>
</tr>
<tr>
<td>12C.6</td>
<td>Monoclonal antibodies in the diagnosis of GVHD</td>
</tr>
<tr>
<td>12C.7</td>
<td>Outlook</td>
</tr>
<tr>
<td>12C.8</td>
<td>References</td>
</tr>
</tbody>
</table>
# Contents

12D Monoclonal antibodies in transplantation: use as therapeutic agents in clinical organ transplantation 340

*M. Giral, J. Dantal, D. Cantarovich, M. Hourmant, R. Baatard, B. Le Mauft, Y. Jacques and J. P. Soulillou*

12D.1 Introduction 340
12D.2 Monoclonal antibodies reacting with all T lymphocytes 341
12D.3 Antibodies that react against a subset of T lymphocytes 346
12D.4 Monoclonal antibodies against interleukin-2 receptors 347
12D.5 Engineered monoclonal antibody molecules: chimeric, 'humanized' and fusion proteins 351
12D.6 Comments 352
12D.7 Acknowledgements 353
12D.8 References 353

13 Monoclonal antibodies and the skin 362

*A. C. Chu and E. Tsele*

13.1 Introduction 362
13.2 Structure of the skin 362
13.3 The keratinocyte 362
13.4 Melanocytes 366
13.5 Langerhans cells 367
13.6 Basement membrane zone 368
13.7 Dermal infiltrates 370
13.8 Cutaneous T cell lymphoma 371
13.9 Benign cellular infiltrates 371
13.10 Adhesion molecules 372
13.11 References 373

14 Monoclonal antibodies in endocrinology 380

*E. Hillhouse and C. H. Self*

14.1 Introduction 380
14.2 Assays of hormones 380
14.3 Generation of suitable monoclonal antibodies 382
14.4 Use of monoclonal antibodies 383
14.5 Specific modification 393
14.6 References 396

15 Monoclonal antibodies in rheumatology 403

*J. D. Isaacs*

15.1 Introduction 403
15.2 Normal immune response 403
15.3 Monoclonal antibodies to control immune responsiveness 406
15.4 Animal models of rheumatological disorders 408
15.5 Monoclonal antibodies in human rheumatic diseases 410
15.6 Adverse effects of monoclonal antibodies 417
15.7 The future 419
15.8 Summary 420
15.9 Acknowledgements 421
15.10 References 421
## Contents

<table>
<thead>
<tr>
<th>16</th>
<th>Technical appendix: monoclonal antibody production methods</th>
<th>429</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.1</td>
<td>Immunization</td>
<td>429</td>
</tr>
<tr>
<td>16.2</td>
<td>Media and general cell culture</td>
<td>429</td>
</tr>
<tr>
<td>16.3</td>
<td>Contamination in tissue culture</td>
<td>430</td>
</tr>
<tr>
<td>16.4</td>
<td>Cryopreservation of cells</td>
<td>431</td>
</tr>
<tr>
<td>16.5</td>
<td>The fusion</td>
<td>433</td>
</tr>
<tr>
<td>16.6</td>
<td>Cloning techniques</td>
<td>436</td>
</tr>
<tr>
<td>16.7</td>
<td>Bulk production of monoclonal antibodies</td>
<td>440</td>
</tr>
<tr>
<td>16.8</td>
<td>Screening techniques</td>
<td>441</td>
</tr>
<tr>
<td>16.9</td>
<td>Monoclonal antibody characterization and purification</td>
<td>449</td>
</tr>
<tr>
<td>16.10</td>
<td>SDS-PAGE and Western blotting</td>
<td>459</td>
</tr>
</tbody>
</table>

**Index**

467
Contributors

Dr R. Baatard
Service de Néphrologie, Immunologie Clinique et Unité de Recherche, INSERM U. 211, CHU Nantes, France

Dr A. Bamias
Imperial Cancer Research Fund Laboratories, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

Dr L. Boström
Department of Clinical Immunology, The Karolinska Institute, Huddinge Hospital, Stockholm, Sweden

Dr D. Cantarovich
Service de Néphrologie, Immunologie Clinique et Unité de Recherche, INSERM U. 211, CHU Nantes, France

Dr A. C. Chu
Unit of Dermatology, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK

Dr J. Cohen
Department of Bacteriology, Royal Postgraduate Medical School, Du Cane Road, London W12 0NN, UK

Dr A. Colfor
Department of Histopathology, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK

Dr D. B. Cook
Department of Clinical Biochemistry, The Medical School, Framlingham Place, Newcastle-upon-Tyne, NE2 4HH, UK

Dr A. Cooke
Immunology Division, Department of Pathology, Cambridge University, Tennis Court Road, Cambridge CB2 1QP, UK

Dr N. S. Courtenay-Luck
Antisoma plc, Samaritan Hospital for Women, 153–173 Marylebone Road, London NW1 5QH, UK
Contributors

Dr J. Dantal
Service de Néphrologie, Immunologie Clinique et Unité de Recherche,
INSERM U. 211, CHU Nantes, France

Dr A. A. Epenetos
Imperial Cancer Research Fund Laboratories, MRC Building, Hammersmith
Hospital, Du Cane Road, London W12 0HS, UK

Dr A. J. T. George
Department of Immunology, Royal Postgraduate Medical School, Du Cane
Road, London W12 0NN, UK

Dr M. Giral
Service de Néphrologie, Immunologie Clinique et Unité de Recherche,
INSERM U. 211, CHU Nantes, France

Dr J. J. Gray
Clinical Microbiology and Public Health Laboratory, Level 6, Addenbrookes
Hospital, Hills Road, Cambridge CB2 2QW, UK

Prof. P. A. Hall
Pathology Department, Ninewells Hospital and Medical School, University of
Dundee, Dundee DD1 9SY, UK

Dr E. Hillhouse
Department of Clinical Biochemistry and Metabolic Medicine, The Medical
School, Framlingham Place, Newcastle-upon-Tyne NE2 4HH, UK

Dr M. Hourmant
Service de Néphrologie, Immunologie Clinique et Unité de Recherche,
INSERM U. 211, CHU Nantes, France

Dr J. D. Isaacs
Division of Immunology, Department of Pathology, Cambridge University,
Tennis Court Road, Cambridge CB2 1QP, UK

Dr Y. Jacques
Service de Néphrologie, Immunologie Clinique et Unité de Recherche,
INSERM U. 211, CHU Nantes, France

Prof. P. J. Lachmann
Molecular Immunopathology Unit, Medical Research Council Centre and
University of Cambridge Clinical School, Cambridge CB2 2QH, UK

Ms H. M. Ladyman
Department of Immunology, Royal Postgraduate Medical School, Du Cane
Road, London W12 0NN, UK

Dr B. Le Mauff
Service de Néphrologie, Immunologie Clinique et Unité de Recherche,
INSERM U. 211, CHU Nantes, France

Dr R. J. Morris
Laboratory of Neurobiology, National Institute for Medical Research, The
Ridgeway, Mill Hill, London NW7 1AA, UK
Contributors

Dr N. M. Parish
Division of Immunology, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK

Mr K. M. Price
Zeneca, Cambridge Research Biochemicals Ltd, Gadbrook Park, Northwich, Cheshire CW9 7RA, UK

Prof. O. Ringden
Department of Clinical Immunology, The Karolinska Institute, Huddinge Hospital, Stockholm, Sweden

Prof. M. A. Ritter
Department of Immunology, Royal Postgraduate Medical School, Du Cane Road, London W12 0NN, UK

Dr M. L. Rose
Immunology Department, Harfield Hospital, Harfield, Uxbridge UB9 6JH, UK

Dr A. Sa’adu
Division of Immunological Medicine, Clinical Research Centre, Northwick Park Hospital, Watford Road, Harrow HA1 3UJ, UK

Prof. C. H. Self
Department of Clinical Biochemistry and Metabolic Medicine, The Medical School, Framlington Place, Newcastle-upon-Tyne, NE2 4HH, UK

Dr S. Songsvilai
Department of Immunology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Dr J. P. Soullou
Service de Néphrologie, Immunologie Clinique et Unité de Recherche, INSERM U. 211, CHU Nantes, France

Dr E. Tsele
Department of Dermatology, Royal Postgraduate Medical School, Du Cane Road, London W12 0NN, UK

Dr T. G. Wrehitt
Clinical Microbiology and Public Health Laboratory, Level 6, Addenbrookes Hospital, Hills Road, Cambridge CB2 2QW, UK

Dr A. Zumla
School of Medicine, University Teaching Hospital, PO Box 50110, Lusaka, Zambia